Psychedelic Clinical Trials Australia

From BurnZero

Psilocybin trials

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 2 ACTRN12621001097831 Treatment-Resistant Depression 2021 Approved Not yet recruiting Ongoing VIC Swinburne University 15 Open 25mg psilocybin with psychotherapy None
Phase 2 ACTRN12621001358831 Generalised Anxiety Disorder 2021 Approved Not yet recruiting Ongoing VIC Monash University 72 Quadruple 25 or 30mg psilocybin with psychotherapy control with psychotherapy
Phase 2 ACTRN12619001225101 Depression and anxiety (in life-threatening illness) 2019 Approved Recruiting Ongoing VIC St Vincent’s Hospital Melbourne 40 Quadruple 25mg psilocybin with psychotherapy placebo with psychotherapy
Phase 1 ACTRN12621000560897 Functional Neurological Disorder 2021 Approved Not yet recruiting Ongoing VIC Austin Health 22 Open 5, 10 then 15mg psilocybin with physiotherapy None
Phase 1 ACTRN12621000578808 Functional Neurological Disorder 2021 Approved Not yet recruiting Ongoing VIC Austin Health 15 Open 0.08-0.1mg/kg psilocybin with physiotherapy None
Phase 1 ACTRN12621001375842 Mechanism 2021 Approved Not yet recruiting Ongoing VIC Monash University 60 Open 19mg psilocybin with meditation 19mg psilocybin without meditation
Phase 1 No ID yet Mechanism 2021 Approved Recruiting Ongoing VIC Monarch Mental Health 100 - n = 100 for psilocybin arm n = 100 for MDMA arm
Phase 3 / Phase 2 ACTRN12622000883718p Brain Activity in Healthy Adults 2022 Other Not yet recruiting Ongoing VIC TMS Clinics Australia 200 Open 25, 30, 35mg psilocybin; or 80 or 120mg MDMA None
Phase 1 ACTRN12621001375842 Brain Activity in Healthy Adults 2021 Approved Not yet recruiting Ongoing VIC Monash University 60 Open 19mg psilocybin Meditation verses No Meditation
Phase 1 ACTRN12622000463774 Methamphetamine Use Disorder 2022 Approved Not yet recruiting Ongoing NSW St Vincent’s Hospital 15 Open Three sessions of 25mg psilocybin with Psychotherapy None

MDMA trials

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 2 ACTRN12619001334190 Late-stage cancer patients, mood and anxiety 2019 Approved Not yet recruiting Ongoing NZ University of Otago 32 Quadruple 120mg MDMA (supplemented 60mg) with psychotherapy None
Phase 1/2 ACTRN12621001078842 PTSD 2021 Approved Not yet recruiting Ongoing WA Edith Cowan University 4 Open 80 or 120mg MDMA (supplemented 40 or 60mg) with psychotherapy None
Phase 1 No ID yet Mechanism 2021 Approved Recruiting Ongoing VIC Monarch Mental Health 100 - n = 100 for MDMA arm n = 100 for psilocybin arm
Phase 0 ACTRN12613000685718 Tinnitus 2013 Approved Complete 2017 NZ The University of Auckland 40 Quadruple 30 or 70mg MDMA Placebo
Observational ACTRN12620001068954 Attitudes of psychotherapists towards MDMA-assisted psychotherapy 2020 Approved Recruiting Ongoing NSW University of Sydney 200 Triple MDMA-assisted psychotherapy questionnaire Fabricated drug-assisted psychotherapy questionnaire
Phase 3 / Phase 2 ACTRN12622000883718p Brain Activity in Healthy Adults 2022 Other Not yet recruiting Ongoing VIC TMS Clinics Australia 200 Open 80 or 120mg MDMA; or 25, 30, 35mg psilocybin None

LSD trials

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 1 ACTRN12621000436875 Microdose, mechanism and creativity 2021 Approved Not yet recruiting Ongoing NZ The University of Auckland 80 Triple 10ug LSD Placebo

Ibogaine trials

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 2 10.1080/00952990.2017.1310218 Addiction, opioid 2012 Approved Complete 2015 NZ University of Otago 14 Open 200mg ibogaine (supplementary dose 400-600mg) None
Phase 1 ACTRN12613000324718 Mechanism 2013 Approved Complete 2013 NZ University of Otago 24 Open 20mg ibogaine Placebo; or DXM control
Observational (Follow Up) 10.1080/00952990.2017.1310218 Addiction, opioid 2015 Approved Complete 2016 NZ University of Otago 14 Open Addiction and depression severity at 12 month follow up post-ibogaine treatment None

DMT

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 1 ACTRN12622000851763 Healthy Adults 2022 Approved Not yet recruiting Ongoing NZ Viridia Life Sciences Australia 48 Open VLS-01 Single-Ascending Dose Intravenous vs Buccal Administration

Iprocin (4-OH-DiPT)

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 1 ACTRN12622000713796p Post Partum Depression and Treatment Resistant Depression 2022 Other Recruiting Ongoing Adelaide Field Trip 32 Blinded FT-104 Normal Saline (0.9% sodium chloride) for injection

Share your opinion